Current Studies

The Northeast Iowa Medical Education Foundation Research Department is working toward solutions for patients living with complex diseases. We do this through clinical trials, which may offer qualified patients an alternate therapy.

Your participation in these studies would assist the pharmaceutical and health care industries in developing new and effective medications for your medical condition. (All medications currently available by prescription underwent clinical study to be FDA approved.) 

To participate in any of the studies listed below, please take a moment to complete a short interest form. Our experienced and professional research colleagues, who have been trained to treat multitudes of medical conditions and illnesses, will follow up to screen you according to the trial’s requirements. They will also review the clinical trial with you, so you understand the treatment, medication and protocols should you join the trial.

Trailblazer ALZ 2, Alzheimer’s

• Active, not enrolling
• Protocol No. I5T-MC-ACCI
  
  
  Sponsor: Eli Lilly
  
  
  This phase 3 clinical trial is for assessment of safety, tolerability and efficacy of Donanemab in Early Symptomatic Alzheimer’s disease. This trial is active and not enrolling patients.

Clear Outcomes, Cardiology

• Active, not enrolling
• Protocol No. 1002-043
  
  
  Sponsor: Esperion
  
  
  This randomized, double-blind, placebo-controlled trial assesses the impact of bempedoic acid in reducing cardiovascular events. This trial is active and not enrolling patients.

Victorion-2-Prevent Study, Cardiovascular

• Enrolling now
• Protocol No. CKJX839B12302
  
  
  Sponsor: Novartis

A randomized, double-blind, placebo-controlled, multicenter trial assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease. This study is enrolling patients now.

Basic inclusion/exclusion criteria (not all criteria are listed)

• 40 years of age or older
• Atorvastatin or Rosuvastatin daily
• Previous MI, stroke, or peripheral vascular disease

To express interest in participating, complete this short online form and a research team member will contact you.

TRAILBLAZER-ALZ3, Alzheimer’s

• Enrolling now
• Protocol No. I5T-MC-AACM
  
  
  Sponsor: Eli Lilly

Now enrolling participants at risk for developing cognitive and functional decline of Alzheimer’s disease for participation in this prevention trial studying Donanemab versus placebo.

Basic inclusion/exclusion criteria (not all criteria are listed)

• 65 years of age or older
• No current memory issues or cognitive decline

To express interest in participating, complete this short online form and a research team member will contact you.

• Enrolling now
• Protocol No. J1G-MC-LAKC
• Sponsor: Eli Lilly
• This study is to assess the safety and efficacy measured by amyloid reduction of remternetug in early symptomatic Alzheimer’s disease.

MercyOne Northeast Iowa research contacts

For more information regarding Trailblazer studies contact Melissa Petersen.

For more information regarding Novartis, Clear Outcomes and Trailrunner studies, contact Sarah Larson.

Contact Research Director Jim Hoehns